FDA Launches Rare Disease Framework Initiative
The U.S. Food and Drug Administration (FDA) has introduced a new initiative called the Rare Disease Framework to improve therapy development for rare diseases. The framework aims to address unique challenges in drug development by considering factors such as disease specifics, patient needs, product types, and realistic evidence generation from small patient populations. This move is intended to streamline regulatory processes while ensuring therapies meet high safety and efficacy standards tailored to the complexities of rare conditions. By adopting a more flexible approach, the FDA hopes to encourage innovation in this niche but critical area of medicine.
Topics: drug development rare diseases regulation